| |JULY 20259LYFIUS PHARMA RESUMES PENICILLIN-G PRODUCTION IN KAKINADA PLANTBIOCON TARGETS CANADA'S LUCRATIVE MARKET FOR OZEMPIC, WEGOVY GENERICSLyfius Pharma Private Limited, a fully owned step-down subsidiary of Aurobindo Pharma, has announced the resumption of production at its Penicillin-G manufacturing facility in Kakinada, Andhra Pradesh.According to the BSE filing, the restart occurs after the Andhra Pradesh Pollution Control Board (APPCB) grants the "Consent to Operate" (CTO). With this result, the company has recovered quickly from the fire event that was reported in April of this year. According to the Medical Dialogues team, the self-ignition of coal is said to have caused the fire that started near the coal crusher area at around 10:00 PM IST. Although some ancillary equipment was damaged in the event, Aurobindo Pharma confirmed that no injuries were reported and that the core manufacturing infrastructure was undamaged.Operations were halted for an estimated 20 to 25 days as a precaution and to allow for the replacement of critical equipment. The business had previously guaranteed that the facility was properly insured and estimated the initial loss from the catastrophe to be about Rs 40 million.Hyderabad, India is home to the headquarters of Aurobindo Pharma Limited, a comprehensive international pharmaceutical corporation. In more than 150 countries, the company develops, produces, and markets a broad variety of active pharmaceutical ingredients, branded specialty pharmaceuticals, and generic medications. The USFDA, UK MHRA, EDQM, Japan PMDA, World Health Organization, Health Canada, South Africa MCC, and Brazil ANVISA are among the regulatory bodies that have authorized the company's 30 manufacturing practices and packaging facilities. Supported by a robust R&D infrastructure, the company's product portfolio is distributed throughout seven primary therapeutic/product areas, including CNS, anti-retroviral, CVS, antibiotics, gastroenterological, anti-diabetics, and antiallergic. POBiocon Ltd is seeking regulatory approval for its generic version of Ozempic (semaglutide) to get into Canada's high growth obesity drug market, aiming for a submission date of September 2025.This would allow for a launch in early 2026 just after Novo Nordisk's patent expires in Canada. Biocon will also be looking to launch generic Wegovy, another biotech blockbuster in semaglutide, as part of a larger pipeline for peptides.The aggressive push comes as demand for GLP-1 receptor agonists, which have increased demand globally, for both weight-loss and diabetes products. Biocon wants to be the first in this lucrative market, projected to be $100 billion worldwide by 2030, with semaglutide generating more than $25 billion alone with sales for 2024. Biocon expects to launch the product with a lower price point, but expects to offer only moderate pricing of 20% off, unlike with small molecule generics typically priced at steep discounts.Biocon has already had regulatory success, with UK approval granted for its liraglutide generic. This approval has allowed Biocon more credibility in its space, following approval it is tested in India and expanding in Latam with further aspirations in Asia-pac. Biocon is aggressively seeking to establish itself as an option in the space following patents expiration as a well-established competitor with the highly competitive space. PO
< Page 8 | Page 10 >